Researchers at University of California San Diego School of Medicine discovered that they can block inflammation in mice with a naturally occurring antibody that binds oxidized phospholipids (OxPL), molecules on cell surfaces that get modified by inflammation. Even while on a high-fat diet, the antibody protected the mice from arterial plaque formation, hardening of the arteries and liver disease, and prolonged their lives.
This study, published June 6 by Nature, marks the first demonstration in a living system that OxPL triggers inflammation and leads to plaque formation. The results also suggest a new approach for preventing or reversing a number of inflammatory diseases.
“Wherever you get inflammation, you get OxPL,” said senior author Joseph Witztum, MD, professor of medicine at UC San Diego School of Medicine. “It doesn’t mean OxPL is the cause, but it definitely plays a major role.” Witztum led the study with first author Xuchu Que, PhD, a senior project scientist at UC San Diego School of Medicine.
Some phospholipids — the molecules that make up cell membranes — are prone to modification by reactive oxygen species, forming OxPL. This event is particularly common in inflammatory conditions such as atherosclerosis, in which artery-blocking plaques form. Prior to this study, researchers were unable to control phospholipid oxidation in a way that would allow them to study its role in inflammation and atherosclerosis.
Witztum, Que and team engineered mice with two special attributes: 1) they have a gene mutation that makes them a good model for atherosclerosis and 2) they generate a piece of an antibody called E06 that’s just enough to bind OxPL and prevent their ability to cause inflammation in immune cells, but not enough to cause inflammation on its own. They fed the mice a high-fat diet.
Here’s what happened: Compared to control mice, the mice with E06 antibodies had 28 to 57 percent less atherosclerosis, even after one year and despite having high levels of cholesterol. The antibody also decreased aortic valve calcification (hardening and narrowing of the aortic valves), hepatic steatosis (fatty liver disease) and liver inflammation. E06 antibody-producing mice had 32 percent less serum amyloid A, a marker of systemic inflammation.
The E06 antibody also prolonged the life of the mice. After 15 months, all of the E06 antibody-producing mice were alive, compared to 54 percent of the control mice.
“We showed for the first time that OxPL are truly pro-inflammatory and pro-atherogenic and, moreover, that they can be counteracted by E06 antibody,” Witztum said. “This suggests that therapies that inactivate OxPL may be beneficial for reducing inflammation in general, and in particular in the case of diseases such as atherosclerosis, aortic stenosis and hepatic steatosis.”
Witztum and team are now testing E06 antibody in mouse models of human diseases linked to inflammation, such as osteoporosis (bone loss) and nonalcoholic steatohepatitis (NASH, a type of liver disease).
The Latest on: Inflammation
via Google News
The Latest on: Inflammation
- Higher HMBGB1 levels associated with obesity, inflammation, and cardiovascular disease in younger black adultson October 8, 2020 at 10:39 pm
A "danger molecule" is higher in the blood of younger black adults than whites, females than males and increases with weight and age, researchers report in the first large, longitudinal study ...
- Trump's symptoms improving; doctors say they will keep monitoring for potential 'inflammation' phaseon October 8, 2020 at 3:54 pm
The physician added they especially want to observe the president as he potentially enters the second, "inflammation" phase of the illness. RELATED: Trump fever free for 24 hours, 'in extremely good ...
- New study highlights links between inflammation and Parkinson's diseaseon October 8, 2020 at 7:08 am
An international collaboration involving researchers from the Luxembourg Center for Systems Biology (LCSB) at the University of Luxembourg established an association between inflammation and ...
- Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammationon October 8, 2020 at 6:34 am
PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today ...
- Study Debunks Claim That This Popular Food Causes Inflammationon October 7, 2020 at 9:30 am
A recent study published in the Journal of the American College of Nutrition found that dairy products and milk proteins do not provoke inflammation.
- Brain inflammation in Parkinson’s disease focus of $3.2 million granton October 6, 2020 at 7:52 am
Study probes inflammation’s role in spreading brain damage; may have implications for MS, Alzheimer’s, other neurodegenerative diseases ...
- Researchers characterize the gene responsible for immune cell death and inflammation during sepsison October 6, 2020 at 4:45 am
Sepsis is caused by the immune system going into over-drive in response to infection. It leads to extreme inflammation that can cause blood clots and block oxygen from reaching vital organs, resulting ...
- Development of Next-Generation Drugs to Inhibit Ravages of Chronic Inflammationon October 5, 2020 at 5:41 am
Multiple studies indicate that chronic inflammation triggers a cascade of disease-causing effects. The condition has also been linked to Alzheimer's disease, cancer, heart disease and diabetes among ...
- CDC: COVID-19 can cause severe organ inflammation in some adultson October 2, 2020 at 11:03 am
Adults with severe COVID-19 risk developing dangerous levels of inflammation simultaneously in several of the body's key organs, including the brain, heart, lung and kidneys, according to CDC research ...
via Bing News